Company / SG&A Expense
Cytek Biosciences, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$58.9M
FY2025
5-year range
$9.4M / $58.9M
FY2021-FY2025
Trend
+36.7%
vs FY2024
Sector context
#141 of 158
Health Care
What the data says
Cytek Biosciences, Inc.'s sg&a expense of $59M is lower than 89% of companies in the Health Care sector (FY2025). Increased from $44M to $59M over the past 2 years.
Based on SEC 10-K filings.
$59M in FY2025 with a 5-year CAGR of +44.5%.
Increased from $44M to $59M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.3%
- 5-Year CAGR
- +44.5%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 158This company $58.9M Sector average $175.9B
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +44.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 36.7% year-over-year.
- Ranks #141 out of 158 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2021.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $58.9M | +36.7% |
| FY2024 | $43.1M | -2.0% |
| FY2023 | $44.0M | +26.8% |
| FY2022 | $34.7M | +270.2% |
| FY2021 | $9.4M | +0.0% |
| FY2020 | $9.4M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026